Restoration of Corneal Transparency by Mesenchymal Stem Cells.
Sharad K Mittal, Masahiro Omoto, Afsaneh Amouzegar...
https://pubmed.ncbi.nlm.nih.gov/27693426/Actively Recruiting
Led by University of Illinois Chicago · Updated on 2026-11-04
38
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness of allogeneic bone marrow-derived mesenchymal stromal cells MSCs delivered locally to promote healing in patients with chronic corneal wounds that do not respond to standard treatments. The study aims to improve clinical outcomes in patients with non-healing corneal epitheliopathy by assessing the safety and efficacy of these MSCs. This Phase II trial will also observe effects on epithelial barrier integrity, scarring, and visual acuity. Participants will receive a single subconjunctival injection of either 3,000,000 MSCs in 150 L or a control injection of 50 L of freezing media or 150 L of normal saline, depending on their group assignment. The follow-up period lasts up to 90 days, during which the treatments effects on the cornea will be monitored. The study uses a randomized, double-masked, parallel design to compare the MSC treatment with the control solution. During the study, participants will undergo regular assessments including visual acuity tests, corneal staining, ocular surface evaluations, measurement of corneal epithelial thickness, and symptom tracking at multiple time points from baseline through day 90. Researchers will measure the primary outcome of corneal epithelial barrier improvement at day 28, along with secondary outcomes such as time to epithelial healing, corneal scarring, neovascularization, and conjunctival injection. Safety and efficacy will be closely monitored throughout the study duration.
CONDITIONS
Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells
A
Ali R Djalilian, MD
C
Charlotte E Joslin, OD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Illinois Chicago
Lead Sponsor
United States Department of Defense
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | MSCs Injection | Sham (Vehicle Control) |
|---|---|---|
| What is it? | Participants receive a single subconjunctival injection of bone marrow-derived allogeneic mesenchymal stromal cells (MSCs) following persistent corneal epithelial disease unresponsive to standard nonsurgical therapy. | Participants receive a sham subconjunctival injection of vehicle control (normal saline solution) with identical follow-up and no active cellular treatment. |
| Role in this trial | Serves as the investigational treatment arm for evaluating efficacy and safety of MSCs for persistent corneal epithelial disease. | Acts as the comparator control arm, simulating intervention minus cellular therapy, to test for effectiveness and rule out placebo effect. |
| Primary use | Being studied as a potential therapy to restore corneal epithelial barrier function and promote healing in eyes with persistent epithelial defects after failure of standard non-surgical care. | Used to provide a comparison group with no active stem cell therapy, maintaining the same procedures without delivering cellular treatment. |
| How is it given or performed? | A single dose of allogeneic MSCs is injected subconjunctivally in the affected eye after eligibility confirmation, using a masked procedure. | A sham injection delivering a similar volume of vehicle (normal saline) is administered subconjunctivally in the affected eye under identical masking conditions. |
| Evidence status | Efficacy and safety in humans are currently being investigated; evidence to date includes preclinical studies and small early-phase trials showing MSCs support corneal healing in animal models and pilot human studies. | Sham injection has no direct therapeutic effect. The comparator is included to control for the placebo effect and standardize follow-up. |
| Important limitations | As an investigational therapy, long-term safety and definitive efficacy in humans are not yet established. Early human trials have not reported major safety concerns but were limited in size. Larger and longer-term outcome data are needed. | Serves only as a masked procedural comparator and does not reflect an active standard therapy or typical clinical practice outside research. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 90 days
Participants receive a single subconjunctival injection of either allogeneic mesenchymal stromal cells or a control solution and are monitored for up to 90 days.
Multiple visits including baseline, days 1-7, 28, 60, and 90
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sharad K Mittal, Masahiro Omoto, Afsaneh Amouzegar...
https://pubmed.ncbi.nlm.nih.gov/27693426/Marta Sacchetti, Alessandro Lambiase
https://pubmed.ncbi.nlm.nih.gov/24672223/Alireza Baradaran-Rafii, Medi Eslani, Scheffer C G Tseng
https://pubmed.ncbi.nlm.nih.gov/21791191/Ahmad Al-Moujahed, James Chodosh
https://pubmed.ncbi.nlm.nih.gov/26226389/Emma Ghazaryan, Yan Zhang, Yuxi He...
https://pubmed.ncbi.nlm.nih.gov/27514011/Fei Li, Shao-Zhen Zhao
https://pubmed.ncbi.nlm.nih.gov/27110252/Glenn C Cockerham, Sonne Lemke, Thomas A Rice...
https://pubmed.ncbi.nlm.nih.gov/25124272/S Bonini, P Rama, D Olzi...
https://pubmed.ncbi.nlm.nih.gov/14631406/Yanling Ma, Yongsheng Xu, Zhifeng Xiao...
https://pubmed.ncbi.nlm.nih.gov/16109757/Young In Yun, Se Yeon Park, Hyun Ju Lee...
https://pubmed.ncbi.nlm.nih.gov/27840134/University of Illinois Chicago
Lead Sponsor
United States Department of Defense
Collaborating Sponsor